NovaBridge Biosciences NovaBridge Biosciences

NovaBridge Biosciences

NBP

Rank in Stocks #19739
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering... NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
Share Price
$0.8499
Last synced: 2026-11-13
Market Cap
$98.35M
Change (1 day)
2.40%
Change (1 year)
-79.52%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
Operating Margin for NovaBridge Biosciences (NBP)
Operating Margin as of November 2026 TTM: 0.00%
According to NovaBridge Biosciences's latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for NovaBridge Biosciences from 2017 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
2026 (TTM) 0.00% 0.00%
2025 0.00% 0.00%
2024 0.00% -100.00%
2023 -11,395.09% -432.98%
2022 3,422.17% -245.43%
2021 -2,353.06% -23,443.85%
2020 10.08% -100.21%
2019 -4,883.23% 498.73%
2018 -815.60% -66.45%
2017 -2,431.25% 0.00%
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
-195.39% -
US
33.87% -
US
-116.04% -
US
25.57% -
AU
31.23% -
BE
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.

Questions about NovaBridge Biosciences's operating margin

What was NovaBridge Biosciences's operating margin in 2025?

In 2025, NovaBridge Biosciences's operating margin was 0.00%, compared with 0.00% in 2024.

How has NovaBridge Biosciences's operating margin changed since 2020?

From 2020 to 2025, NovaBridge Biosciences's operating margin was highest in 2022 (3,422.17%) and lowest in 2023 (-11,395.09%).

How does NovaBridge Biosciences's operating margin compare with similar companies?

NovaBridge Biosciences's operating margin (0.00%) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.